Bayer AG announced today the opening of its new Research and Innovation Center at Kendall Square in Boston-Cambridge, Massachusetts (U.S.A.), expanding further the company’s footprint into one of the world’s most innovative pharmaceutical research and development locations. Representing a total $140M USD investment into the area, Bayer’s 62,100-square-foot building houses a new center of precision molecular oncology research equipped with state-of-the-art laboratories and offices for the development of novel targeted cancer therapies for patients.
Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
June 30, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022